GLP-1 agonists and their next-gen successors may still be center stage in the red-hot obesity space, but newly launched ...

Johnson & Johnson Executive Vice President and Chief External Innovation and Medical Officer William Hait, M.D., Ph.D., will ...

Amid an organizational reset, Bayer’s SVP and Global Head of Biotech Jens Vogel, Ph.D., has hit the exits after four years ...

Vyaire Medical has put up the for-sale sign, as it files for Chapter 11 bankruptcy following dropping demand in the wake of ...

GE HealthCare is switching up the leadership of its divisions, as well as the alignment of some of its segments, to better ...

Lokavant has released a new artificial intelligence solution it claims can help contract research organizations and sponsors ...

It remains to be seen whether Sage Therapeutics’ dalzanemdor can improve function in patients with Huntington's disease.

Charles River Laboratories has launched a new program to come up with an animal-free alternative to inhalation toxicology ...

In a document (PDF) released publicly June 5, the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) ...

Eli Lilly’s Alzheimer’s treatment sailed through an FDA advisory committee meeting Monday, with panelists praising the ...

After posting preliminary results from the first-in-human trial of its closed-loop neuromodulation implant for urinary ...

Abbott’s diabetes division thought joining the over-the-counter market looked so nice they did it twice. The company has ...